Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate

Patients taking suppressive doses of T4 are thought to have accelerated bone loss and increased risk of osteoporosis. We therefore randomize 55 patients taking suppressive doses of T4 to treatment with pamidronate (APD) 30 mg i.v. every 3 months for 2 yr (APD/T4), or placebo (placebo/T4). Patients h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 1998-07, Vol.83 (7), p.2324-2330
Hauptverfasser: ROSEN, H. N, MOSES, A. C, GARBER, J, ROSS, D. S, LEE, S. L, FERGUSON, L, CHEN, V, LEE, K, GREENSPAN, S. L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2330
container_issue 7
container_start_page 2324
container_title The journal of clinical endocrinology and metabolism
container_volume 83
creator ROSEN, H. N
MOSES, A. C
GARBER, J
ROSS, D. S
LEE, S. L
FERGUSON, L
CHEN, V
LEE, K
GREENSPAN, S. L
description Patients taking suppressive doses of T4 are thought to have accelerated bone loss and increased risk of osteoporosis. We therefore randomize 55 patients taking suppressive doses of T4 to treatment with pamidronate (APD) 30 mg i.v. every 3 months for 2 yr (APD/T4), or placebo (placebo/T4). Patients had measurements of bone mineral density (BMD) of the spine, hip, radius, and total body every 6 months for 2 yr. There was no significant bone loss at any site in the placebo/T4 group. Ninety five percent confidence intervals excluded a rate of bone loss > 0.89%/yr for the spine and > 0.31%/yr at the total hip. When men were excluded from the analysis, there still was no significant bone loss for the placebo/T4 group, and confidence intervals did not change. The APD/T4 group showed increases in spine (4.3%, P = 0.0001), total hip (1.4%, P < 0.05), and trochanteric (3.0%, P = 0.0001) BMDs. In conclusion, premenopausal women and men on suppressive therapy with T4 do not lose bone rapidly, and are not at increased risk of developing osteoporosis. A regimen of 30 mg APD given every 3 months for 2 yr causes significant suppression of bone resorption and increases in BMD, and may be an acceptable alternative treatment for osteoporosis in patients who cannot tolerate oral bisphosphonates.
doi_str_mv 10.1210/jc.83.7.2324
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80007235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17202575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-4d75e9e604a43bb2dc82cbd8d0d6be5fa93d0d1065ecc7a0f3c8894bc2b094dc3</originalsourceid><addsrcrecordid>eNqFkU2L1TAUhoMo453RnVshC3E1vearTetOB79gQBAFdyU9OWVyaZOapDPWv-UftPVeBneuztdz3nPgJeQZZ3suOHt1gH0t93ovpFAPyI43qiw0b_RDsmNM8KLR4vtjcp7SgTGuVCnPyFlTVbxickd-fzHehtH9QktzdGagoaeTGZ2NwZuM1Pm1zA59TvTO5Ruab5YYnKVgPGCkr-nb4JFa9MnlhbpEfcg0op1hlewWmuZpipiSu12pkDBtF_6K_HQeL2k3523LeYho0nEHFhgcrL0czS36MKd_f3pCHvVmSPj0FC_It_fvvl59LK4_f_h09ea6AKmqXCirS2ywYsoo2XXCQi2gs7Vltuqw7E0j15SzqkQAbVgvoa4b1YHoWKMsyAvy8qg7xfBjxpTb0SXAYTAe15famjGmhSz_C3ItmCj1Bl4eQYghpYh9O0U3mri0nLWbme0B2lq2ut3MXPHnJ925G9Hewyf31vmL09wkMEMfV0tcuseEZKqshfwDIVKsOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17202575</pqid></control><display><type>article</type><title>Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>ROSEN, H. N ; MOSES, A. C ; GARBER, J ; ROSS, D. S ; LEE, S. L ; FERGUSON, L ; CHEN, V ; LEE, K ; GREENSPAN, S. L</creator><creatorcontrib>ROSEN, H. N ; MOSES, A. C ; GARBER, J ; ROSS, D. S ; LEE, S. L ; FERGUSON, L ; CHEN, V ; LEE, K ; GREENSPAN, S. L</creatorcontrib><description>Patients taking suppressive doses of T4 are thought to have accelerated bone loss and increased risk of osteoporosis. We therefore randomize 55 patients taking suppressive doses of T4 to treatment with pamidronate (APD) 30 mg i.v. every 3 months for 2 yr (APD/T4), or placebo (placebo/T4). Patients had measurements of bone mineral density (BMD) of the spine, hip, radius, and total body every 6 months for 2 yr. There was no significant bone loss at any site in the placebo/T4 group. Ninety five percent confidence intervals excluded a rate of bone loss &gt; 0.89%/yr for the spine and &gt; 0.31%/yr at the total hip. When men were excluded from the analysis, there still was no significant bone loss for the placebo/T4 group, and confidence intervals did not change. The APD/T4 group showed increases in spine (4.3%, P = 0.0001), total hip (1.4%, P &lt; 0.05), and trochanteric (3.0%, P = 0.0001) BMDs. In conclusion, premenopausal women and men on suppressive therapy with T4 do not lose bone rapidly, and are not at increased risk of developing osteoporosis. A regimen of 30 mg APD given every 3 months for 2 yr causes significant suppression of bone resorption and increases in BMD, and may be an acceptable alternative treatment for osteoporosis in patients who cannot tolerate oral bisphosphonates.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.83.7.2324</identifier><identifier>PMID: 9661603</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Analysis of Variance ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Bone Density - drug effects ; Depression, Chemical ; Diphosphonates - therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Endocrinopathies ; Female ; Humans ; Infusions, Intravenous ; Male ; Malignant tumors ; Medical sciences ; Middle Aged ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - physiopathology ; Thyroid. Thyroid axis (diseases) ; Thyroxine - therapeutic use</subject><ispartof>The journal of clinical endocrinology and metabolism, 1998-07, Vol.83 (7), p.2324-2330</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-4d75e9e604a43bb2dc82cbd8d0d6be5fa93d0d1065ecc7a0f3c8894bc2b094dc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2304582$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9661603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROSEN, H. N</creatorcontrib><creatorcontrib>MOSES, A. C</creatorcontrib><creatorcontrib>GARBER, J</creatorcontrib><creatorcontrib>ROSS, D. S</creatorcontrib><creatorcontrib>LEE, S. L</creatorcontrib><creatorcontrib>FERGUSON, L</creatorcontrib><creatorcontrib>CHEN, V</creatorcontrib><creatorcontrib>LEE, K</creatorcontrib><creatorcontrib>GREENSPAN, S. L</creatorcontrib><title>Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Patients taking suppressive doses of T4 are thought to have accelerated bone loss and increased risk of osteoporosis. We therefore randomize 55 patients taking suppressive doses of T4 to treatment with pamidronate (APD) 30 mg i.v. every 3 months for 2 yr (APD/T4), or placebo (placebo/T4). Patients had measurements of bone mineral density (BMD) of the spine, hip, radius, and total body every 6 months for 2 yr. There was no significant bone loss at any site in the placebo/T4 group. Ninety five percent confidence intervals excluded a rate of bone loss &gt; 0.89%/yr for the spine and &gt; 0.31%/yr at the total hip. When men were excluded from the analysis, there still was no significant bone loss for the placebo/T4 group, and confidence intervals did not change. The APD/T4 group showed increases in spine (4.3%, P = 0.0001), total hip (1.4%, P &lt; 0.05), and trochanteric (3.0%, P = 0.0001) BMDs. In conclusion, premenopausal women and men on suppressive therapy with T4 do not lose bone rapidly, and are not at increased risk of developing osteoporosis. A regimen of 30 mg APD given every 3 months for 2 yr causes significant suppression of bone resorption and increases in BMD, and may be an acceptable alternative treatment for osteoporosis in patients who cannot tolerate oral bisphosphonates.</description><subject>Adult</subject><subject>Analysis of Variance</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Density - drug effects</subject><subject>Depression, Chemical</subject><subject>Diphosphonates - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Malignant tumors</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Thyroid Neoplasms - drug therapy</subject><subject>Thyroid Neoplasms - physiopathology</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Thyroxine - therapeutic use</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2L1TAUhoMo453RnVshC3E1vearTetOB79gQBAFdyU9OWVyaZOapDPWv-UftPVeBneuztdz3nPgJeQZZ3suOHt1gH0t93ovpFAPyI43qiw0b_RDsmNM8KLR4vtjcp7SgTGuVCnPyFlTVbxickd-fzHehtH9QktzdGagoaeTGZ2NwZuM1Pm1zA59TvTO5Ruab5YYnKVgPGCkr-nb4JFa9MnlhbpEfcg0op1hlewWmuZpipiSu12pkDBtF_6K_HQeL2k3523LeYho0nEHFhgcrL0czS36MKd_f3pCHvVmSPj0FC_It_fvvl59LK4_f_h09ea6AKmqXCirS2ywYsoo2XXCQi2gs7Vltuqw7E0j15SzqkQAbVgvoa4b1YHoWKMsyAvy8qg7xfBjxpTb0SXAYTAe15famjGmhSz_C3ItmCj1Bl4eQYghpYh9O0U3mri0nLWbme0B2lq2ut3MXPHnJ925G9Hewyf31vmL09wkMEMfV0tcuseEZKqshfwDIVKsOA</recordid><startdate>19980701</startdate><enddate>19980701</enddate><creator>ROSEN, H. N</creator><creator>MOSES, A. C</creator><creator>GARBER, J</creator><creator>ROSS, D. S</creator><creator>LEE, S. L</creator><creator>FERGUSON, L</creator><creator>CHEN, V</creator><creator>LEE, K</creator><creator>GREENSPAN, S. L</creator><general>Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>19980701</creationdate><title>Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate</title><author>ROSEN, H. N ; MOSES, A. C ; GARBER, J ; ROSS, D. S ; LEE, S. L ; FERGUSON, L ; CHEN, V ; LEE, K ; GREENSPAN, S. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-4d75e9e604a43bb2dc82cbd8d0d6be5fa93d0d1065ecc7a0f3c8894bc2b094dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Analysis of Variance</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Density - drug effects</topic><topic>Depression, Chemical</topic><topic>Diphosphonates - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Malignant tumors</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Thyroid Neoplasms - drug therapy</topic><topic>Thyroid Neoplasms - physiopathology</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Thyroxine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROSEN, H. N</creatorcontrib><creatorcontrib>MOSES, A. C</creatorcontrib><creatorcontrib>GARBER, J</creatorcontrib><creatorcontrib>ROSS, D. S</creatorcontrib><creatorcontrib>LEE, S. L</creatorcontrib><creatorcontrib>FERGUSON, L</creatorcontrib><creatorcontrib>CHEN, V</creatorcontrib><creatorcontrib>LEE, K</creatorcontrib><creatorcontrib>GREENSPAN, S. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROSEN, H. N</au><au>MOSES, A. C</au><au>GARBER, J</au><au>ROSS, D. S</au><au>LEE, S. L</au><au>FERGUSON, L</au><au>CHEN, V</au><au>LEE, K</au><au>GREENSPAN, S. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>1998-07-01</date><risdate>1998</risdate><volume>83</volume><issue>7</issue><spage>2324</spage><epage>2330</epage><pages>2324-2330</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>Patients taking suppressive doses of T4 are thought to have accelerated bone loss and increased risk of osteoporosis. We therefore randomize 55 patients taking suppressive doses of T4 to treatment with pamidronate (APD) 30 mg i.v. every 3 months for 2 yr (APD/T4), or placebo (placebo/T4). Patients had measurements of bone mineral density (BMD) of the spine, hip, radius, and total body every 6 months for 2 yr. There was no significant bone loss at any site in the placebo/T4 group. Ninety five percent confidence intervals excluded a rate of bone loss &gt; 0.89%/yr for the spine and &gt; 0.31%/yr at the total hip. When men were excluded from the analysis, there still was no significant bone loss for the placebo/T4 group, and confidence intervals did not change. The APD/T4 group showed increases in spine (4.3%, P = 0.0001), total hip (1.4%, P &lt; 0.05), and trochanteric (3.0%, P = 0.0001) BMDs. In conclusion, premenopausal women and men on suppressive therapy with T4 do not lose bone rapidly, and are not at increased risk of developing osteoporosis. A regimen of 30 mg APD given every 3 months for 2 yr causes significant suppression of bone resorption and increases in BMD, and may be an acceptable alternative treatment for osteoporosis in patients who cannot tolerate oral bisphosphonates.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>9661603</pmid><doi>10.1210/jc.83.7.2324</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 1998-07, Vol.83 (7), p.2324-2330
issn 0021-972X
1945-7197
language eng
recordid cdi_proquest_miscellaneous_80007235
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current)
subjects Adult
Analysis of Variance
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Bone Density - drug effects
Depression, Chemical
Diphosphonates - therapeutic use
Double-Blind Method
Drug Administration Schedule
Endocrinopathies
Female
Humans
Infusions, Intravenous
Male
Malignant tumors
Medical sciences
Middle Aged
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - physiopathology
Thyroid. Thyroid axis (diseases)
Thyroxine - therapeutic use
title Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A58%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20trial%20of%20pamidronate%20in%20patients%20with%20thyroid%20cancer%20:%20Bone%20density%20is%20not%20reduced%20by%20suppressive%20doses%20of%20thyroxine,%20but%20is%20increased%20by%20cyclic%20intravenous%20pamidronate&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=ROSEN,%20H.%20N&rft.date=1998-07-01&rft.volume=83&rft.issue=7&rft.spage=2324&rft.epage=2330&rft.pages=2324-2330&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.83.7.2324&rft_dat=%3Cproquest_cross%3E17202575%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17202575&rft_id=info:pmid/9661603&rfr_iscdi=true